Literature DB >> 28256082

Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan.

M Sugimoto1, H Ban1, D Hira2, T Kamiya2, T Otsuka3, O Inatomi3, S Bamba3, T Terada2, A Andoh3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28256082     DOI： 10.1111/apt.13959

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  5 in total

1.  Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.

Authors:  Satoshi Shinozaki; Hiroyuki Osawa; Yoshikazu Hayashi; Yoshimasa Miura; Alan Kawarai Lefor; Hironori Yamamoto
Journal:  Biomed Rep       Date:  2021-02-01

Review 2.  Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Front Pharmacol       Date:  2019-01-15       Impact factor: 5.810

Review 3.  Efficacy of Vonoprazan for Helicobacter pylori Eradication.

Authors:  Shu Kiyotoki; Jun Nishikawa; Isao Sakaida
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

4.  Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers.

Authors:  Taketo Otsuka; Mitsushige Sugimoto; Hiromitsu Ban; Toshiro Nakata; Masaki Murata; Atsushi Nishida; Osamu Inatomi; Shigeki Bamba; Akira Andoh
Journal:  World J Gastrointest Endosc       Date:  2018-05-16

5.  Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis.

Authors:  Shailja C Shah; Adam Tepler; Cecilia P Chung; Giovanni Suarez; Richard M Peek; Adriana Hung; Christianne Roumie; Neeraj Narula
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.